Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and genetic association studies on susceptibility to the disease are limited. We sought to identify possible overlap of genetic susceptibility loci between pancreatic ductal adenocarcinoma (PDAC) and pNEN; therefore, PDAC susceptibility variants (n = 23) from Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 3277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the odds associated with pNEN risk, disease onset and tumor characteristics. Main effect analyses showed four PDAC susceptibility variants-rs9854771, rs1561927, rs9543325 and O. Obazee et al. | 361 rs10919791 to be associated with pNEN risk. Subsequently, only associations with rs9543325, rs10919791 and rs1561927 were noteworthy with false positive report probability (FPRP) tests. Stratified analyses considering age at onset (50-year threshold), showed rs2736098, rs16986825 and rs9854771 to be associated with risk of developing pNEN at a younger age. Stratified analyses also showed some single nucleotide polymorphisms to be associated with different degrees of tumor grade, metastatic potential and functionality. Our results identify known GWAS PDAC susceptibility loci, which may also be involved in sporadic pNEN etiology and suggest that some genetic mechanisms governing pathogenesis of these two entities may be similar, with few of these loci being more influential in younger cases or tumor subtypes.
Introduction
Pancreatic neuroendocrine neoplasms (pNEN) arise from islet cells and comprise less than 5% of all new pancreatic neoplasms (1) . Heterogeneous in tumor behavior and clinical symptoms, pNENs account for 10% of neuroendocrine tumors and have a 5-year mortality rate of 60% (1, 2) . Compared to the more common exocrine pancreatic ductal adenocarcinoma (PDAC), pNENs are characterized by a rather 'silent' clinical course and generally present at a relatively earlier age (median age at diagnosis 53-60 years, and 72 years for PDAC) (1) . Majority (40-90%) of pNENs are non-functional (i.e. do not secrete hormones that cause systemic effects) thus constituting a clinical and prognostic challenge for physicians. Surgical resection is currently the primary curative therapy option for both malignancies, however, most patients unfortunately exhibit unresectable tumors at diagnosis (3) , stressing the need for improved risk stratification and timely diagnostic biomarkers. Familial clustering observed in population-based studies among PDAC and other cancer patients provide evidence of an inherited basis for sporadic pNEN (1) . Although there is no clear link between environmental exposures and risk of developing pNEN, an overlap of risk factors in PDAC and pNENs is likely (4) . Increased interest in these neoplasms has become evident in the last decade, but despite this, molecular understanding of pNENs is still insufficient to drive clinical interventions. Recent exome and whole genome sequencing studies describing the genetic basis of pNENs among Caucasians (5,6) have implicated somatic mutations in four core pathways: activation of mTOR signaling, DNA damage repair, chromatin modification and altered telomere length in tumorigenesis. Genome wide association (GWAS) or candidate gene or pathway studies investigating the etiology of pNENs have been reasonably limited by small sample size, when compared with PDAC for which 23 common risk variants have so far been identified through GWAS or studies focusing on genes situated in well-known pleiotropic regions (7) (8) (9) (10) (11) . Based on the rationale that known common genetic susceptibility loci for sporadic PDAC may also modify the risk of developing pNEN, we genotyped 369 pNEN cases from a retrospectively enrolled population within the PANcreatic Disease ReseArch (PANDoRA) consortium and compared genotype frequencies of all known PDAC GWAS susceptibility variants to over 3200 control subjects from the same consortium. We tested their possible association with overall sporadic pNEN risk and within pNEN subgroups.
Materials and methods

Selection of subjects and polymorphisms
Demographic characteristics of subjects within the PANDoRA consortium have been described previously (12) although the number of neuroendocrine cases within PANDoRA has increased since that publication. Written informed consent and biospecimens (blood, tissue or genomic DNA) were obtained for all subjects and ethical approval for the PANDoRA study protocol received from the Ethics commission of the Medical Faculty Heidelberg. Only sporadic (non-familial) pNEN cases not associated with genetic syndromes such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau syndrome, von Recklinghausen disease (neurofibromatosis NF-1) and tuberous sclerosis complex were used in this study. Twenty-three single nucleotide polymorphisms (SNPs) reaching genomewide significance and suggestive levels (up to 5 × 10 -7 ) were selected from GWAS publications in PDAC among Caucasians (7) (8) (9) (10) . pNEN tumors were classified according to the World Health Organization 2010 classification system (13) .
Genotyping and quality control
SNPs were genotyped in 369 pNEN cases and 3277 controls using TaqMan allelic discrimination (Applied Biosystems) and KASPar (LGC Genomics) assays according to manufacturers' instructions. Post-PCR allelic discrimination was done on the 7900HT real-time PCR system (Life Technologies) and data analyzed using the affiliated SDS software (v.2.3). Internal replicates (7% of all samples) and negative controls were included to assess the fidelity of genotype calls. Deviation from Hardy-Weinberg equilibrium was checked using the Pearson's χ 2 test.
Statistical analyses
We evaluated associations [odds ratios (OR) and 95% confidence intervals (CI)] between SNPs and pNEN risk using unconditional multivariate logistic regression in STATA v.11 (StataCorp LP). Tests were done using a codominant inheritance model, with adjustment for potential confounding variables-age, geographical origin and gender. We used a nominal significance threshold (P < 0.05) since the selected SNPs were based on prior evidence of their association with pancreatic cancer. Noteworthiness of SNP associations with P < 0.05 were tested using the Bayesian false positive report probability (FPRP) test which takes the observed P value, statistical power of the test and prior probabilities for the associations into account (14) . All selected SNPs bore a high prior possibility of being associated with pNEN risk (π = 0.2) as recommended by Wacholder et al. (14) , and only SNP associations with P < 0.05 and π < 0.2 were considered 'noteworthy'. To evaluate the effect of SNPs on pNEN onset, we first performed a case-only analysis comparing genotype distributions among cases (>50 years) with their younger counterparts (≤50 years) while adjusting for gender and geographical origin. We also compared genetic associations from three additional models: cases ≤50 years versus controls of all ages (EOP1), cases >50 years versus controls of all ages (TOP) and cases up to 50 years versus controls up to 50 years (EOP2 
Microarray data screening
To gain additional insight to the transcriptomic profiles of these gene regions in human pancreatic islet cells, we explored expression profiling data from the Gene Expression Omnibus (GEO) database (Accession number GSE43795); this study characterized mRNA and microRNA expression profiles in solid-pseudopapillary neoplasms of pancreas (n = 14), ductal adenocarcinoma (n = 6), pancreatic neuroendocrine tumors (n = 6) and non-neoplastic pancreatic tissue samples (n = 5) (17) . Results were downloaded in text format and GEO2R queries (http://www.ncbi.nlm. nih.gov/geo/geo2r/) applied to assess differentially expressed genes in pNEN compared to non-neoplastic pancreas tissue samples. GEO2R is an R programming language-based dataset analysis tool that compares two or more groups of samples under the same experimental conditions and analyzes almost any GEO series (18) . P values were adjusted to correct for false-positives due to multiple testing using Benjamini and Hochberg false discovery rate method and genes that met the cut-off criteria of P adjusted < 0.05 and |logFC| > 1.0 were screened out as differentially expressed genes.
Results
Baseline characteristics of the study population are summarized in Table 1 . The median age at diagnosis in this study was 57 years, congruent with previous literature reports. Genotypes for most SNPs, except rs505922 (P = 0.04) were distributed in accordance to Hardy-Weinberg equilibrium among controls. Duplicated samples showed genotyping concordance rate of 99.6%. Genotyping data for those subjects with genotyping completion rates below 75% (n = 35) were excluded from all statistical analyses.
Overall pNEN risk analyses
Minor allele frequencies, genotype distributions, risk estimates [odds ratios (OR) and 95% confidence intervals (CI)] of all polymorphisms investigated in this study are summarized in Table 2 . rs9543325 was associated with higher risk of pNEN (OR 1.63, 95% CI (1.10-2.47), P hom = 0.02). rs10919791, rs1561927 and rs9854771 were associated with lower risk of pNEN (OR 0.65, 95% CI (0.46-0.93), P het = 0.02; OR 0.71, 95% CI (0.55-0.92), P het = 0.01 and OR 0.76, 95% CI (0.58-0.99), P het = 0.04 respectively). Subsequent testing of these findings using FPRP with a prior of 0.2 showed that only associations with rs10919791 (FPRP = 0.13), rs9543325 (FPRP = 0.15) and rs1561927 (FPRP = 0.07) were noteworthy. The association with rs9854771 failed the noteworthiness test (FPRP = 0.25).
Stratified analyses based on age at pNEN onset
With stratification according to age at disease onset (≤50 years versus >50 years) among successfully genotyped pNEN cases, we observed significant differences between genotype groups for rs16986825 (ZNRF) (OR 2.67, 95% CI (1.57-4.55), P het = 0.0003 and OR 2.27, 95% CI (1.37-3.77), P = 0.002 in the recessive model); rs2736098 (TERT) (OR 3.71, 95% CI (1.36-10.10), P hom = 0.01; and rs9854771 (TP63) (OR 1.85, 95% CI (1.11-3.10), P het = 0.02 and OR 1.69, 95% CI (1.04-2.75), P = 0.03 in the recessive model (Table 3) . FPRP tests were similarly applied using a prior probability of 0.2 and associations between early pNEN onset and rs16986825 (FPRP < 0.01 in both models), rs2736098 (FPRP = 0.08) and rs9854771 (FPRP = 0.14), were noteworthy. For rs9854771, our observed association for the recessive model was not noteworthy (FPRP = 0.22). Since pNENs are diagnosed roughly 10 years earlier than PDAC, we also performed the same stratified analyses with threshold at 40 years, and only the TERT SNPs (rs2736098 and rs2853677) were significantly associated with higher risk of developing pNEN at 40 years or younger, albeit with extremely small group sizes (results not shown). Results from alternative 
Differentially expressed genes based on microarray data screening
Reasoning that the additional gene expression profiles of all 26 genes harboring or located close to the SNPs investigated in this study would amplify our ability to identify relevant underlying biological processes, we screened a GEO superseries dataset including six pNEN, five healthy pancreas (controls) and six ductal adenocarcinoma tissue samples. Based on the inclusion criteria of P adjusted < 0.05 and |logFC| > 1.0, five of these genes-nuclear receptor subfamily 5 group A member 2 (NR5A2), v-myc avian myelocytomatosis viral oncogene homolog (MYC), Krüppel-like factor (KLF) 5 (KLF5) and chymotrypsinogen genes, CTRB1 and CTRB2 were under expressed in pNEN compared to normal pancreas tissue ( 
Discussion
By investigating known GWAS PDAC susceptibility loci (MAF ≥5%), our study has identified the possible role of these loci in the risk of developing pNEN. Combined with gene expression analyses, we report for the first time, few loci which may also be involved in genetic mechanisms influencing pNEN tumorigenesis, age at onset and tumor characteristics. These findings confirm that some susceptibility loci are shared by both entities. Interestingly, most known environmental risk factors associated with increased pNEN risk are also associated with PDAC risk (4) . Although rarity and lack of predictive biomarkers for early-stage diagnosis or risk stratification of healthy individuals in both entities are two common features of these neoplasms, understanding their molecular mechanisms remains essential and advantageous. It is common albeit controversial knowledge that pancreatic ductal cells are 'potential facultative stem cells' capable of being reprogrammed into cells that closely resemble islet cells in vivo (19, 20) . Whether the shared genetic susceptibility is due to the origin of both these tumor types from a common pluripotent precursor cell, or a phenomenon linked with the reported capacity of islet cells to transdifferentiate to ductal cells (21, 22 ) is currently unknown. Among explanations proposed for the transdifferentiation of pancreas cells, a largely favored one in pathogenesis is based on the hypothesis that tumor stroma mimics the regulatory role of pancreatic embryonic mesenchyme in duct and endocrine development, to induce the switch between ductules and endocrine cells (23, 24) . A second hypothesis based on multiple lines of evidence also suggests that tumor cells may originate from a common pluripotent cell which matures into two phenotypically different cell lines (25) , and this pluripotent cell expresses transcription factors such as PDX1 and SOX9 which are involved in pancreatic development and homeostasis (26) . Our study, which comprised of 369 pNEN cases and 3277 healthy controls from the international PANDoRA consortium, represents the largest of such studies performed to date. Recent attempts to delineate the mutational landscape of pNENs through whole genome sequencing (6), have implicated activation of mTOR signaling as one of the core pathways commonly altered in these neoplasms. In overall risk analyses, four SNPs (rs9854771, rs9543325, rs1561927 and rs10919791) showed associations with sporadic pNEN at P < 0.05. Adjustment for multiple comparisons was not applied to the nominal significance threshold (P < 0.05) since selected SNPs were based on prior evidence of their association with pancreatic cancer. Using the FPRP model in overall analyses, Based on predefined cutoff value of adjusted-P < 0.05 and |log2 fold-change| > 1, genes which are differentially expressed in both groups are in bold.
*P value adjusted using Benjamini and Hochberg method (False discovery rate).
only associations with rs10919791, rs9543325 and rs1561927 reached noteworthiness with a prior probability of 0.2. rs1561927 in MIR1208/PVT1 was associated with a 29% lower risk of developing pNEN among heterozygotes, which is similar to the original report in PDACs [allelic OR 0.87 95% CI (0.83-0.92) (9) ]. This intronic SNP maps to a locus associated with suggested long-distance interactions with MYC and PVT1 promoters in multiple cancers (9) . rs9543325, an intergenic SNP in chr13q22.1 which is frequently deleted in several cancers (8) was associated with a 37% increased risk of developing pNEN (for subjects with CC genotype), higher than risk estimates from the original study in PDACs [OR 1.26 95% CI (1.18-1.35)] (8) . Genes closest to this locus are KLF5, KLF12, PIBF1, DIS3 and BORA, which range up to 586 kb in distance from rs9543325. Krüppel-like factor (KLF) 5 and 12 are members of a family of zinc-finger transcription factors reported to exhibit tumor-suppressor and oncogenic activity, respectively, in various human cancers (27) . KLF5 is involved in transcriptional activation of PI3K/Akt signaling, BORA (encoding aurora kinase A activator) is known to regulate cell proliferation and overexpressed in tumors (28) . PIBF1 (encoding progesterone immunomodulatory binding factor 1) is speculated to be involved in progesterone-dependent immunomodulation with higher levels in tumors (28) . Aberrant expression of DIS3 has been implicated in many cancers and plays a crucial role in gene regulation and small RNA processing (29) . rs10919791 lies in the first intron of NR5A2 (chr1q32.1) which plays crucial roles in pancreatic function and development (30) . In the current study, rs10919791 was associated with a 35% lower risk of developing pNEN among heterozygotes, similar to the original estimate among PDACs (OR het 0.76 (0.68-0.84)) (8) .
The bioinformatics approach with a GEO2R microarray dataset including pancreatic neuroendocrine tumors (n = 6) and non-neoplastic pancreatic tissue samples (n = 5), was used to augment results from our study and explore the plausible role of these genes in pNEN development. Interestingly, MYC, KLF5, NR5A2, CTRB1 and CTRB2 appeared down-regulated among pNENs compared to non-neoplastic pancreatic tissue in the microarray dataset, further implicating these genes in pNEN tumorigenesis. To substantiate these findings, we performed a similar comparison of expression profiles of these genes in PDAC (n = 6) versus healthy pancreas, which showed differential expression of all genes but KLF5 in the same manner. To the best of our knowledge, this is the only publicly available dataset that includes expression data of pNEN. The data we observed in this dataset corroborate our findings of the association analysis. Nevertheless the very small sample size of this dataset is a cause for concern, and these data should be taken with caution.
Additional stratified analyses based on age at onset and tumor characteristics (Tables 3 and 4 , respectively), despite relatively small genotype strata for some SNPs, also shed light on susceptibility loci that may be useful for improved risk stratification and possible choice of therapy based on tumor characteristics. The contribution of rs7310409 to pNEN development is conceivable given that pleiotropic HNF1A plays a crucial role, as a tumor suppressor, in the transcriptional regulation in endocrine and exocrine pancreas development and homeostasis (31) . This locus has also been reported as a prime candidate mediating susceptibility to type 2 diabetes among Caucasians (32) . Although the role of p53 homolog, p63 in pancreatic cancer is poorly understood, it has been implicated in tumorigenesis and metastasis via cell cycle arrest and apoptotic mechanisms (33) . Our observed association between heterozygous carriers of this polymorphism and metastatic pNEN tumors is therefore plausible.
Nevertheless, the small size observed in each stratum due to the rarity of these neoplasms, raises a valid concern on the possible interpretation of our findings. We therefore applied the FPRP approach instead of a much lower P value adjusted for multiple comparisons, as the latter would have resulted in unnecessarily low power for our high prior probability hypotheses, particularly in these neoplasms where collection of larger number of cases is unrealistic. Notwithstanding, all noteworthy findings reported here must be interpreted with caution and replicated in possibly larger and independent studies.
The major strengths of this study are its relatively large size, considering the low incidence of pNEN and data analysis approaches applied to minimize the effect of potentially confounding factors and more importantly evaluate the noteworthiness of our findings. The integration of gene expression profiling provides valuable insight to shared genetic correlations and expands the probable margins of our results. A limitation of our investigations however, was that due to lack of clinical information, we could not stratify subjects based on familial history of PDAC or other non-genetic factors such as history of diabetes mellitus.
Taken together, these results illuminate genetic similarities between the two main groups of pancreatic neoplasms, suggesting that common variations at three known PDAC susceptibility loci -13q22.1 (TP63, rs9543325), 1q32.1 (NR5A2, rs10919791) and 8q24.21 (MIR1208/PVT1, rs1561927) potentially influence tumorigenesis of pancreatic beta cells in a similar manner as in exocrine pancreatic cells. Our results also suggest that genetic predisposing factors vary on the basis of age at pNEN onset as well as tumor characteristics. Striking similarities between embryogenesis and tumorigenesis which have become more apparent in past decades taken together with our genetic findings may provide groundwork for future evaluation of the potential usability of these loci as predictive biomarkers and in risk assessment. Functional studies are also warranted to better understand the biological implications of these loci in pancreatic hormone-producing (endocrine) and enzyme-producing (exocrine) cell function.
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